Personalis, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019. The filing was dated March 25, 2020. Although the request references 2019 Q4, this is an annual Form 10-K; quarterly information is included for the three months ended December 31, 2019.
Business Context
Personalis is a cancer genomics company providing sequencing and data-analysis services to biopharmaceutical companies, government entities, universities, and nonprofits. Its NeXT Platform profiles approximately 20,000 human genes, tumor DNA and RNA, and immune-system characteristics from limited tissue samples. The company also provides whole-genome sequencing services to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP), is developing a broad liquid-biopsy assay, and launched the NeXT Dx diagnostic in January 2020.
The company operates as one reportable segment. Substantially all revenue is generated in the United States, and the laboratory and headquarters are located in Menlo Park, California.
Financial Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $65.2 million | $37.8 million | +73% |
| Gross profit | $22.1 million | $11.8 million | +88% |
| Gross margin | 33.9% | 31.2% | +2.7 pts |
| Loss from operations | $(22.4) million | $(13.8) million | Loss increased |
| Operating margin | (34.4%) | (36.5%) | Improved |
| Net loss | $(25.1) million | $(19.9) million | Loss increased |
| Net margin | (38.5%) | (52.6%) | Improved |
| Net loss per share | $(1.39) | $(6.49) | Improved due largely to share increase |
| Cash used in operating activities | $(18.1) million | $5.6 million | Declined |
| Capital expenditures | $8.4 million | $7.9 million | Increased |
Revenue growth was driven primarily by VA MVP volume. VA MVP revenue increased 134% to $43.5 million, while revenue from all other customers increased 13% to $21.7 million. VA MVP represented 67% of total revenue, and Pfizer represented 13%. The top five customers accounted for 90% of revenue.
Costs of revenue increased 66% to $43.1 million. Research and development expense increased 57% to $22.4 million, and selling, general and administrative expense increased 96% to $22.1 million, reflecting higher personnel, product-development, public-company, professional-service, and infrastructure costs. Stock-based compensation increased to $4.9 million from $1.3 million.
Fourth-quarter 2019 revenue was $18.2 million, gross profit was $6.6 million, and net loss was $6.6 million. Fourth-quarter gross margin was approximately 36.2% and net margin was approximately (36.6%).
Liquidity, Cash Flow, and Debt
- Cash and cash equivalents were $55.0 million at December 31, 2019.
- Short-term investments were $73.2 million, producing combined cash, cash equivalents, and short-term investments of $128.3 million, versus $19.7 million at December 31, 2018.
- Working capital was $89.6 million, compared with $(28.3) million in 2018.
- The company had no outstanding debt at year-end. It repaid its $20.0 million Growth Capital Loan in August 2019 and recorded a $1.7 million loss on extinguishment.
- Customer deposits included in contract liabilities were $36.0 million, including approximately $32.5 million from one customer.
- Contracted but unrecognized revenue was $68.8 million at year-end, which management expected to recognize over the following 15 months.
- Management stated that existing cash, cash equivalents, and marketable securities were expected to fund operations for at least the next 12 months, subject to assumptions that could prove incorrect.
Material Changes Versus 2018
- Revenue increased 73%, led by a substantial increase in VA MVP sequencing volume.
- Gross margin improved from 31.2% to 33.9%, but the operating loss increased because operating expenses grew faster than revenue.
- Operating cash flow changed from $5.6 million provided in 2018 to $18.1 million used in 2019, partly reflecting the net loss and a $6.9 million reduction in contract liabilities.
- The June 2019 IPO generated approximately $139.8 million of net proceeds and resulted in the conversion of all outstanding preferred stock into common stock.
- Cash was redeployed into short-term investments and laboratory equipment; investing cash outflows increased to $81.6 million.
- The company became debt-free and ended the year with positive stockholders’ equity of $106.7 million, compared with a deficit of $106.4 million in 2018.
- The material weakness in internal control over financial reporting identified for 2017 and 2018 was reported as remediated during the fourth quarter of 2019 through additions to accounting and finance personnel. The company’s independent auditor was not required to provide an internal-control attestation.
Outlook, Risks, and Unusual Items
- Management planned to launch NeXT Liquid Biopsy in 2020 and intended to expand NeXT Dx, initially targeting clinical cancer centers and biopharmaceutical clinical trials. No NeXT Dx revenue was recognized in 2019.
- The VA MVP contract had renewal options and orders expected to generate revenue into 2021, but the VA may terminate the agreement for convenience, and orders depend on funding, enrollment, sample volume, and government priorities.
- Customer concentration is significant: VA MVP accounted for 67% of 2019 revenue, and the company has no minimum-purchase commitment from many customers.
- The company relies on Illumina as the sole supplier of sequencers, related reagents, and maintenance services. Supply disruption or a transition to other equipment could interrupt operations and require test revalidation.
- Personalis operates one principal laboratory. Damage, regulatory suspension, natural disaster, supplier disruption, or other interruption could materially impair service delivery.
- The company markets its diagnostic tests as laboratory-developed tests and relies on the FDA’s enforcement discretion. Future FDA, CLIA, state, or other regulatory requirements could increase costs, delay commercialization, or require premarket clearance or approval.
- The filing identifies ongoing risks from competition, intellectual-property claims, data privacy and cybersecurity incidents, clinical-trial failures at customers, employee retention, and the need for additional capital if cash consumption increases.
- COVID-19 developments occurring after year-end affected the company’s operations. California and local shelter-in-place orders limited office and laboratory access, delayed customer samples, and created potential supply-chain, productivity, and demand disruptions. The filing does not provide a quantified financial impact.
- There were no material legal proceedings or off-balance-sheet arrangements as of December 31, 2019.
Key Facts Investors Should Verify
- Whether VA MVP funding, sample volumes, renewal decisions, and pricing support revenue growth beyond 2020.
- Whether non-VA customer revenue can diversify the business and reduce the 67% VA MVP concentration.
- Conversion of NeXT Platform pilots into recurring, larger-volume customer programs and the commercial adoption of NeXT Dx and liquid biopsy products.
- Revenue growth relative to research, commercial, laboratory, and public-company cost growth, including the path toward profitability.
- Cash burn, capital expenditures, customer deposit obligations, and the duration of the stated liquidity runway.
- Operational dependence on Illumina and the capacity and resilience of the company’s single laboratory.
- COVID-19 effects on sample receipts, clinical trials, supply availability, customer demand, and 2020 results.
- Regulatory developments affecting laboratory-developed tests, diagnostic commercialization, data privacy, and reimbursement.
- Potential dilution from 4.7 million outstanding stock options, restricted stock units, employee purchase-plan shares, and outstanding warrants.